Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-26

Clinical Trial Update: Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of ixazomib with pegylated IFN-alpha 2b in metastatic renal cell carcinoma was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ixazomib (ixazomib)
  • pegylated IFN-alpha 2b (pegylated interferon alpha-2b)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Metastatic Renal Cell Carcinoma, RCC | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-09-26